Business Services

Pharmaceutical Business Services – News, analysis and company profiles

Showing 15 posts of 2456 posts found.

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

March 22, 2023 Business Services

VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have …

Hadassah Selects YonaLink’s EHR-to-EDC Clinical Trial Platform to Securely and Seamlessly Integrate Clinical Care and Research Data

March 22, 2023 Business Services

Boston, March 22, 2023 — YonaLink, a clinical trial software provider, today announced its EHR-to-EDC data integration platform has been …

Bio-Rad Launches PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers

March 22, 2023 Business Services

HERCULES, Calif. — March 15, 2023 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science …

InvoX Pharma’s F-star announces licence agreement with Takeda for second novel next-generation immuno-oncology bispecific antibody

March 22, 2023 Business Services

LONDON, United Kingdom, March, 22, 2023 (GLOBE NEWSWIRE): InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited …

Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression

March 22, 2023 Business Services

Boston, Massachusetts March 22, 2023 – Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify …

ELLAB LAUNCHES NEW MONITORING SOLUTION FOR LIFE-SAVING PRODUCTS

March 22, 2023 Business Services

Ellab has launched a new continuous monitoring solution for the biotech and pharmaceutical sectors, which accurately monitors critical processes 24/7. …

CANARY WHARF ATTRACTS LIFE SCIENCES FOCUSED STARTUPS AND SCALEUPS TO ITS TECHNOLOGY COMMUNITY AT LEVEL39

March 22, 2023 Business Services

22 March 2023: The development of a major life science cluster at Canary Wharf continues to build momentum with a …

Sequana Medical announces additional patents for DSR® in China and the United States

March 22, 2023 Business Services

Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

March 21, 2023 Business Services

OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …

Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.

March 20, 2023 Business Services

Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …

NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)

March 20, 2023 Business Services

MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …

New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

March 20, 2023 Business Services

STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

March 20, 2023 Business Services

Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

March 17, 2023 Business Services

Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …
The Gateway to Local Adoption Series

Latest content